Cellectar Biosciences Statistics Share Statistics Cellectar Biosciences has 2.68M
shares outstanding. The number of shares has increased by 0.03%
in one year.
Shares Outstanding 2.68M Shares Change (YoY) 0.03% Shares Change (QoQ) 0% Owned by Institutions (%) 11.3% Shares Floating 2.59M Failed to Deliver (FTD) Shares 4,306 FTD / Avg. Volume 0.9%
Short Selling Information The latest short interest is 66.9K, so 2.34% of the outstanding
shares have been sold short.
Short Interest 66.9K Short % of Shares Out 2.34% Short % of Float 2.35% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -7.37 and the forward
PE ratio is -0.36.
Cellectar Biosciences's PEG ratio is
0.12.
PE Ratio -7.37 Forward PE -0.36 PS Ratio 0 Forward PS 3 PB Ratio 22.98 P/FCF Ratio -6.89 PEG Ratio 0.12
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cellectar Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.58,
with a Debt / Equity ratio of 0.03.
Current Ratio 2.58 Quick Ratio 2.58 Debt / Equity 0.03 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-4.05M Employee Count 11 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 66K Effective Tax Rate -0.15%
Stock Price Statistics The stock price has increased by -91.94% in the
last 52 weeks. The beta is 0.42, so Cellectar Biosciences's
price volatility has been higher than the market average.
Beta 0.42 52-Week Price Change -91.94% 50-Day Moving Average 7.15 200-Day Moving Average 16.49 Relative Strength Index (RSI) 38.7 Average Volume (20 Days) 478,143
Income Statement
Revenue n/a Gross Profit n/a Operating Income -51.78M Net Income -44.58M EBITDA -44.22M EBIT -44.52M Earnings Per Share (EPS) -1.22
Full Income Statement Balance Sheet The company has 23.29M in cash and 494K in
debt, giving a net cash position of 22.79M.
Cash & Cash Equivalents 23.29M Total Debt 494K Net Cash 22.79M Retained Earnings -247.34M Total Assets 16.04M Working Capital 8.87M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -47.58M
and capital expenditures -104.19K, giving a free cash flow of -47.69M.
Operating Cash Flow -47.58M Capital Expenditures -104.19K Free Cash Flow -47.69M FCF Per Share -1.3
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CLRB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CLRB is $28,
which is 522.2% higher than the current price. The consensus rating is "Buy".
Price Target $28 Price Target Difference 522.2% Analyst Consensus Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 24, 2025. It was a
backward
split with a ratio of 1:30.
Last Split Date Jun 24, 2025 Split Type backward Split Ratio 1:30
Scores Altman Z-Score -30.04 Piotroski F-Score 0
